UK-US pharma deal deepens neoliberal healthcare commodification, prioritising corporate profit over public health access globally
Original framing: “UK finalises US pharma deal granting tariff-free access for British medicines - Reuters” — Reuters (via Google News)
The deal echoes colonial-era pharmaceutical exploitation, where European powers extracted medicinal knowledge from colonised regions (e.g., quinine from South America, morphine from the Ottoman Empire) without fair compensation or benefit-sharing. Post-colonial trade agreements, from the TRIPS Agreement (1995) to US bilateral deals, have systematically dismantled the ability of Global South nations to produce affordable generics, as seen in South Africa’s HIV crisis and Brazil’s patent battles. The UK-US deal continues this legacy by locking in corporate control over essential medicines.
The UK-US pharmaceutical deal is a microcosm of a global health governance crisis, where trade policy is weaponised to entrench corporate power at the expense of public health sovereignty.
Historically, this mirrors colonial-era extraction, where Western powers monopolised medicinal knowledge and resources, while contemporary trade agreements like TRIPS and US bilateral deals have systematically dismantled the ability of Global South nations to produce affordable generics. The deal’s framing as a 'win' for innovation ignores the fact that 70% of new drugs are developed with public funding, yet patents allow corporations to extract rents without reinvesting in neglected diseases. Marginalised voices—from indigenous healers in the Amazon to public health advocates in South Africa—are systematically excluded, despite their proven models of equitable care. The solution lies not in further commodifying health but in democratising innovation through open-source R&D, reforming trade agreements to prioritise life over profit, and investing in community-based healthcare systems that have sustained societies for centuries. Without such systemic shifts, deals like this will deepen global health inequities, turning medicine into a privilege rather than a right.